

December 13, 2006

## Notice of the Result of Acquisition of the Company's Own Shares Through ToSTNeT-2

Japan, December 13, 2006 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it completed acquisition of its own shares in the market.

### Particulars

1. Class of shares acquired:	Common stock of the Company
2. Total number of shares acquired:	12,429,400 shares
3. Value of the transaction:	¥ 5,180
4. Period of acquisition:	December 13, 2006
5. Method of acquisition:	Purchased through ToSTNeT-2 (closing price transaction) of the Tokyo Stock Exchange

### (Reference 1)

Resolution of the Board of Directors on October 4, 2006

- Reasons for acquisition of its own shares:	In order to improve capital efficiency and enhance return to shareholders
- Class of shares to be acquired:	Common stock of the Company
- Number of shares to be acquired:	30 million shares (maximum) (equivalent to 5.32% of a total of issued shares)
- Aggregate amount of acquisition cost:	¥ 150 billion (maximum)
- Period of acquisition:	From October 5, 2006 to February 28, 2007

### (Reference 2)

Cumulative total of the its own shares after Resolution of the Board of Directors on October 4, 2006

1. Total number of shares purchased:	27,299,700 shares
2. Total value of purchase:	¥140,682,749,000

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 <a href="http://www.astellas.com">http://www.astellas.com</a>